NSORB

Serial Number 87071783
Registration 5658730
700

Registration Progress

Application Filed
Jun 15, 2016
Under Examination
Approved for Publication
Nov 6, 2018
Published for Opposition
Nov 6, 2018
Registered
Jan 22, 2019

Attorney Assistance

Section 8 (6-Year) Declaration Due (Based on registration date 2019-01-22) (Grace Period Filing)
Due: Jul 22, 2025 Grace Period - 8 days
Original deadline was Jan 22, 2025 (overdue)

Trademark Image

NSORB

Basic Information

Serial Number
87071783
Registration Number
5658730
Filing Date
June 15, 2016
Registration Date
January 22, 2019
Published for Opposition
November 6, 2018
Drawing Code
4000

Status Summary

Current Status
Active
Status Code
700
Status Date
Jan 22, 2019
Registration
Registered
Classes
005

Rights Holder

SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED

16
Address
17-B, MAHAL INDUSTRIAL AREA,
Off- MAHAKALI CAVES ROAD, ANDHERI (East)
MUMBAI 400093
IN

Ownership History

SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED

Original Applicant
16
MUMBAI IN

SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED

Owner at Publication
16
MUMBAI IN

SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED

Original Registrant
16
MUMBAI IN

Legal Representation

Attorney
Craig Kuchii

USPTO Deadlines

Next Deadline
In Grace Period
Section 8 (6-Year) Declaration Due (Based on registration date 2019-01-22)
Due Date
January 22, 2025
Grace Period Ends
July 22, 2025
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

37 events
Date Code Type Description Documents
Jan 22, 2024 REM1 E COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED Loading...
Jan 22, 2019 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Nov 6, 2018 PUBO A PUBLISHED FOR OPPOSITION Loading...
Nov 6, 2018 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Oct 17, 2018 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Oct 4, 2018 PREV O LAW OFFICE PUBLICATION REVIEW COMPLETED Loading...
Oct 1, 2018 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Oct 1, 2018 GNEA O EXAMINERS AMENDMENT E-MAILED Loading...
Oct 1, 2018 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Oct 1, 2018 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Oct 1, 2018 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Sep 26, 2018 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Sep 26, 2018 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Sep 25, 2018 ERSI I TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Loading...
Mar 30, 2018 CNSI R SUSPENSION INQUIRY WRITTEN Loading...
Mar 30, 2018 GNSI S INQUIRY TO SUSPENSION E-MAILED Loading...
Mar 30, 2018 GNS2 O NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED Loading...
Mar 28, 2018 RCCK S SUSPENSION CHECKED - TO ATTORNEY FOR ACTION Loading...
Sep 27, 2017 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Sep 27, 2017 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Sep 27, 2017 CNSL R SUSPENSION LETTER WRITTEN Loading...
Sep 27, 2017 GNSL S LETTER OF SUSPENSION E-MAILED Loading...
Sep 27, 2017 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Loading...
Sep 21, 2017 ERSI I TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Loading...
Mar 29, 2017 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Mar 29, 2017 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Mar 23, 2017 ALIE A ASSIGNED TO LIE Loading...
Mar 23, 2017 RCCK S SUSPENSION CHECKED - TO ATTORNEY FOR ACTION Loading...
Mar 23, 2017 CNSI R SUSPENSION INQUIRY WRITTEN Loading...
Mar 23, 2017 GNSI S INQUIRY TO SUSPENSION E-MAILED Loading...
Mar 23, 2017 GNS2 O NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED Loading...
Sep 19, 2016 DOCK D ASSIGNED TO EXAMINER Loading...
Sep 19, 2016 CNSL R SUSPENSION LETTER WRITTEN Loading...
Sep 19, 2016 GNSL F LETTER OF SUSPENSION E-MAILED Loading...
Sep 19, 2016 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Loading...
Jun 21, 2016 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jun 18, 2016 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005